专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO0137812A2 GASTRORETENTIVE CONTROLLED RELEASE PHARMACEUTICAL DOSAGE FORMS 审中-公开
标题翻译：气体控制释放药物剂型
公开(公告)号：WO0137812A2
公开(公告)日：2001-05-31
申请号：PCT/IL0000774
申请日：2000-11-20
申请人： YISSUM RES DEV CO , FRIEDMAN MICHAEL , KLAUSNER EYTAN , LAVY ERAN , HOFFMAN AMNON
发明人： FRIEDMAN MICHAEL , KLAUSNER EYTAN , LAVY ERAN , HOFFMAN AMNON
IPC分类号： A61K47/30 , A61K9/08 , A61K9/107 , A61K9/14 , A61K9/20 , A61K9/22 , A61K9/26 , A61K9/40 , A61K9/52 , A61K31/525 , A61K47/10 , A61K47/14 , A61K47/24 , A61K47/32 , A61K47/36 , A61K47/38 , A61K47/42 , A61P1/04
CPC分类号： A61K9/2086
摘要： Pharmaceutical gastroretentive drug delivery system for the controlled release of an active agent in the gastrointestinal tract, which comprises: (a) a single- or multi-layered matrix having a two- or three-dimensional geometric configuration comprising a polymer that does not retain in the stomach more than a conventional dosage form selected from (1) degradable polymers that may be hydrophilic polymers not instantly soluble in gastric fluids, enteric polymers substantially insoluble at pH less than 5.5 and/or hydrophobic polymers and mixtures thereof; (2) non-degradable polymers; and any mixtures of (1) and (2); (b) a continuous or non-continuous membrane, that does not retain in the stomach more than a conventional dosage form, affixed or attached to said matrix, the membrane comprising at least one polymer having a substantial mechanical strength; and (c) a drug; wherein the matrix when affixed or attached to said membrane prevents evacuation from the stomach of said delivery system for a period of time of from about 3 to about 24 hours. The system may further comprise a shielding layer. The delivery system is particularly suitable for the delivery of drugs having a narrow absorption window in the gastrointestinal tract, drugs intended for local treatment of the gastrointestinal tract and drugs degraded in the colon, and is intended for human and veterinary use.
摘要翻译：用于在胃肠道中控制释放活性剂的药物胃滞留药物递送系统，其包括：（a）具有二维或三维几何构型的单层或多层基质，其包含不保留在胃超过常规剂型，选自（1）可降解的聚合物，其可以是不能立即溶于胃液的亲水性聚合物，在pH小于5.5时基本上不溶解的肠溶聚合物和/或疏水聚合物及其混合物; （2）不可降解聚合物; 和（1）和（2）的任何混合物; （b）连续或不连续的膜，其不比常规剂型保留在固定或附着到所述基质上，所述膜包含至少一种具有显着机械强度的聚合物; 和（c）药物; 其中当固定或连接到所述膜时所述基质防止从所述递送系统的胃排出约3至约24小时的时间。该系统还可以包括屏蔽层。递送系统特别适合于在胃肠道中递送具有窄吸收窗口的药物，用于局部治疗胃肠道的药物和在结肠中降解的药物，并且用于人和兽医用途。

2. 发明申请

WO2006072948A3 GASTRO-RETENTIVE DIAGNOSTIC ASSEMBLIES 审中-公开
标题翻译：胃气道诊断装置
公开(公告)号：WO2006072948A3
公开(公告)日：2006-11-02
申请号：PCT/IL2006000017
申请日：2006-01-05
申请人： INTEC PHARMA LTD , YISSUM RES DEV CO , AFARGAN MICHEL , KIRMAYER DAVID , LAPIDOT NOA , FRIEDMAN MICHAEL , HOFFMAN AMNON
发明人： AFARGAN MICHEL , KIRMAYER DAVID , LAPIDOT NOA , FRIEDMAN MICHAEL , HOFFMAN AMNON
IPC分类号： A61K9/48 , A61K49/18 , A61K51/12
CPC分类号： A61K49/1818 , A61K9/0065 , A61K49/0002 , A61K51/1251
摘要： The present invention provides a gastro-retentive diagnostic assembly (GRDA) for use in determining a condition of a subject's gastrointestinal tract (GI tract), comprising a folded single or multi-layered device comprising a diagnostic utility, such as a contrasting agent, the device prior to folding being essentially planar, and included in a delivery system for oral intake, the delivery system being adapted to release the device once in the stomach, whereupon release said device unfolds into an unfolded shape that results in the retention of the device in the stomach. Further provided are methods of determining a condition of a subject's GI tract by the use of the GRDA of the invention, as well as uses of a single or multi-layered device comprising a diagnostic utility when in a folded or unfolded shape, and method of preparing the GRDA of the invention.
摘要翻译：本发明提供了一种用于确定受试者的胃肠道（GI道）的状况的胃滞留诊断组件（GRDA），其包括折叠的单层或多层设备，其包括诊断实用程序，例如造影剂，折叠前的装置基本上是平面的，并且包括在用于口服进入的输送系统中，所述输送系统适于在胃中释放装置一次，于是释放所述装置展开成展开形状，导致装置保持在肚子还提供了通过使用本发明的GRDA来确定受试者的胃肠道状况的方法，以及当处于折叠或展开形状时包括诊断用途的单层或多层设备的使用，以及方法准备本发明的GRDA。

3. 发明公开

EP0941064A4 PHARMACEUTICAL PREPARATIONS FOR THE CONTROLLED RELEASE OF beta -LACTAM ANTIBIOTICS 失效
标题翻译：药抗生素的β内酰胺控释
公开(公告)号：EP0941064A4
公开(公告)日：2001-12-12
申请号：EP97911421
申请日：1997-11-13
申请人： YISSUM RES DEV CO
发明人： KATZHENDLER IFAT , HOFFMAN AMNON , FRIEDMAN MICHAEL
IPC分类号： A61K9/20 , A61K9/26 , A61K31/43 , A61K31/545 , A61K9/10 , A61K9/22 , A61K9/24 , A61K9/66 , A61K47/32 , A61K47/36 , A61K47/38 , A61K47/42 , A61K47/44
CPC分类号： A61K31/545 , A61K9/2027 , A61K9/205 , A61K9/2054 , A61K31/43 , A61K2300/00
摘要： The present invention relates to a pharmaceutical controlled-release oral drug delivery system comprising as active ingredient at least one β-lactam antibiotic agent, having a specific absorption site in the small intestine in combination with a polymeric matrix, optionally further containing additional pharmaceutically acceptable constituents, wherein at least 50 % of the β-lactam antibiotic agent are released from the matrix within from about 3 to about 4 hours from oral administration and the remainder of the pharmaceutical agent is released at a controlled rate. The drug delivery system according to the invention optionally further comprises a β-lactamase inhibitor, preferably in combination with amoxicillin and/or amoxicillin trihydrate as the active ingredient. The polymeric matrix of the pharmaceutical controlled-release oral drug delivery system of the invention may be of hydrophilic and/or hydrophobic nature and the delivery system may further comprise pharmaceutically acceptable additive. The pharmaceutical controlled-release oral drug delivery system of the invention is preferably in dosage unit form.

4. 发明专利

AU2016347651A1 Novel cannabinoid formulations 未知
公开(公告)号：AU2016347651A1
公开(公告)日：2018-05-17
申请号：AU2016347651
申请日：2016-10-26
申请人： YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD
发明人： DOMB ABRAHAM J , HOFFMAN AMNON , IZGELOV DVORA
IPC分类号： A61K9/127 , A61K9/51 , A61K31/436
摘要： The invention provides formulations and methods for improving oral bioavailability of cannabinoid compositions.

5. 发明专利

CA2609951A1 BACKBONE CYCLIZED MELANOCORTIN STIMULATING HORMONE (A S ) ANALOGS 未知
公开(公告)号：CA2609951A1
公开(公告)日：2006-12-07
申请号：CA2609951
申请日：2006-05-31
申请人： YISSUM RES DEV CO
发明人： GILON CHAIM , LINDE YANIV , HOFFMAN AMNON , HESS SHMUEL
IPC分类号： C07K7/56 , A61K38/00 , C07K14/685
摘要： Novel backbone cyclized peptides which are a-melanocortin stimulating hormone (aMSH) analogs, having improved Melanocortin-4 receptor agonist activity are disclosed. The backbone cyclized peptide analogs disclosed possess unique and superior properties over other analogs, such as metabolic stability, increased oral bioavailability, improved intestinal permeability and pharmacological activity in-vivo. Pharmaceutical compositions comprising the backbone cyclized aMSH analogs, and methods of using such compositions for the treatment of metabolic disorders including obesity are also disclosed.

6. 发明专利

IL285348D0 Par4 derived peptides, analogs and uses thereof 未知
公开(公告)号：IL285348D0
公开(公告)日：2021-09-30
申请号：IL28534821
申请日：2021-08-03
申请人： HADASIT MED RES SERVICE , YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD , RACHEL BAR SHAVIT , HOFFMAN AMNON , GILON CHAIM
发明人： RACHEL BAR-SHAVIT , HOFFMAN AMNON , GILON CHAIM
IPC分类号： A61K38/00 , C07K14/72
摘要： The present invention provides peptides derived from the cytoplasmic region of protease-activated receptors 4 (PAR4) as well as analogs and cyclic analogs, such as backbone cyclic analogs, of these peptides. Pharmaceutical compositions comprising said peptides, analog, cyclic analogs and well as conjugates thereof are provides as well. The peptides, analogs and conjugates of the present invention and pharmaceutical composition comprising thereof have several uses including treating cancer and inhibiting interactions between PARs and protein comprising PH-domain.

7. 发明专利

BRPI0610955A2 未知
公开(公告)号：BRPI0610955A2
公开(公告)日：2010-08-03
申请号：BRPI0610955
申请日：2006-05-31
申请人： YISSUM RES DEV CO
发明人： GILON CHAIM , HOFFMAN AMNON , LINDE YANIV , HESS SHMUEL
IPC分类号： C07K7/56 , A61K38/00 , C07K14/685
摘要： Backbone cyclized peptides which are alpha-melanocortin stimulating hormone (alphaMSH) analogs, having improved Melanocortin-4 receptor agonist activity are disclosed. The backbone cyclized peptide analogs disclosed possess unique and superior properties over other analogs, such as metabolic stability, increased oral bioavailability, improved intestinal permeability and pharmacological activity in-vivo. Pharmaceutical compositions that include the backbone cyclized alphaMSH analogs, and methods of using such compositions for the treatment of metabolic disorders including obesity are also disclosed.

8. 发明专利

AU783062B2 Gastroretentive controlled release pharmaceutical dosage forms 未知
公开(公告)号：AU783062B2
公开(公告)日：2005-09-22
申请号：AU1647701
申请日：2000-11-20
申请人： YISSUM RES DEV CO
发明人： FRIEDMAN MICHAEL , KLAUSNER EYTAN , LAVY ERAN , HOFFMAN AMNON
IPC分类号： A61K47/30 , A61K9/08 , A61K9/107 , A61K9/14 , A61K9/20 , A61K9/22 , A61K9/26 , A61K9/40 , A61K9/52 , A61K31/525 , A61K47/10 , A61K47/14 , A61K47/24 , A61K47/32 , A61K47/36 , A61K47/38 , A61K47/42 , A61P1/04

9. 发明专利

AT300286T 未知
公开(公告)号：AT300286T
公开(公告)日：2005-08-15
申请号：AT00978993
申请日：2000-11-20
申请人： YISSUM RES DEV CO
发明人： FRIEDMAN MICHAEL , KLAUSNER EYTAN , LAVY ERAN , HOFFMAN AMNON
IPC分类号： A61K47/30 , A61K9/08 , A61K9/107 , A61K9/14 , A61K9/20 , A61K9/22 , A61K9/26 , A61K9/40 , A61K9/52 , A61K31/525 , A61K47/10 , A61K47/14 , A61K47/24 , A61K47/32 , A61K47/36 , A61K47/38 , A61K47/42 , A61P1/04

10. 发明专利

CA3111385A1 SUSTAINED-RELEASE INJECTABLE ANTIBIOTICAL FORMULATION 未知
公开(公告)号：CA3111385A1
公开(公告)日：2020-03-12
申请号：CA3111385
申请日：2019-09-05
申请人： YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD , AGRINNOVATION YISSUM G P LTD
发明人： FRIEDMAN MICHAEL , KIRMAYER DAVID , NUDELMAN ZAKHAR , HOFFMAN AMNON , LAVY ERAN , BAR-HAI AYALA , GATI IRITH
IPC分类号： A61K9/08 , A61K31/165 , A61K31/43 , A61K31/7048 , A61K47/18 , A61K47/38 , A61P31/04
摘要： Provided herein are compositions of injectable antibiotics for veterinary use. The compositions are characterized by forming a gel at animal physiological temperature, said gel being characterized by a stable and repeatable release profile of the antibiotic. The compositions comprise high loading of drug in poloxamer solutions with addition of a co-solvent, and preferably with an addition of a cellulose derivative at least partially soluble in organic solvents. Methods of treatment of veterinary infections are also provided.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式